Cite
HARVARD Citation
Bagot, M. et al. (2019). IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet oncology. 20 (8), pp. 1160-1170. [Online].